Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
- Authors: Kesaeva L.A.1, Bulanov A.Y.2, Finashutina Y.P.1, Tikhonova V.V.1, Solopova O.N.1, Misyurina E.N.2, Kasatkina N.N.1, Lyzhko N.A.1, Misyurin V.A.1, Turba A.A.3, Solodovnik A.A.1, Soldatova I.N.3, Misyurin A.V.3
-
Affiliations:
- N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
- City Clinical Hospital No 52 of the Moscow Healthcare Department
- GeneTechnology
- Issue: Vol 6, No 2 (2019)
- Pages: 48-54
- Section: RESEARCH ARTICLES
- Published: 27.07.2019
- URL: https://umo.abvpress.ru/jour/article/view/218
- DOI: https://doi.org/10.17650/2313-805X-2019-6-2-48-54
- ID: 218
Cite item
Full Text
Abstract
About the authors
L. A. Kesaeva
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: kelar-22@mail.ru
ORCID iD: 0000-0001-8277-8649
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
A. Yu. Bulanov
City Clinical Hospital No 52 of the Moscow Healthcare Department
Email: fake@neicon.ru
3 Pekhotnaya St., Moscow 123182 Russian Federation
Yu. P. Finashutina
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
V. V. Tikhonova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-8658-2819
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
O. N. Solopova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-5465-6094
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
E. N. Misyurina
City Clinical Hospital No 52 of the Moscow Healthcare Department
Email: fake@neicon.ru
3 Pekhotnaya St., Moscow 123182 Russian Federation
N. N. Kasatkina
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-4735-977X
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
N. A. Lyzhko
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0003-3834-5816
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
V. A. Misyurin
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-0762-5631
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
A. A. Turba
GeneTechnology
Email: fake@neicon.ru
104 Profsoyuznaya St., 117485 Moscow Russian Federation
A. A. Solodovnik
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0001-8399-057X
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
I. N. Soldatova
GeneTechnology
Email: fake@neicon.ru
104 Profsoyuznaya St., 117485 Moscow Russian Federation
A. V. Misyurin
GeneTechnology
Email: fake@neicon.ru
ORCID iD: 0000-0003-1349-2879
104 Profsoyuznaya St., 117485 Moscow Russian Federation
References
- Misyurin A.V. Molecular pathogenesis of the myeloproliferative diseases. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2009;2(3):211–21. (In Russ.).
- Chi J., Pierides Ch., Mitsidou A. et al. A sensitive detection method for MPLW515L or MPLW515K mutation in myeloproliferative disorders. Euro J Exp Bio 2014;4(5):33–6.
- Tutaeva V., Misurin A.V., Michiels J.J. et al. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. Hematology 2007;12(6):473–9. doi: 10.1080/10245330701384005.
- Klampfl T., Gisslinger H., Harutyunyan A.S. Somatic mutations of ca lreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379–89. doi: 10.1056/NEJMoa1311347.
- Nangalia J., Massie C.E., Baxter E.J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(25):2391–405. doi: 10.1056/NEJMoa1312542.
- Michalak M., Corbett E.F., Mesaeli N. et al. Calreticulin: one protein, one gene, many functions. Biochem J 1999;2:281–92.
- Zapun A., Darby N.J., Tessier D.C. Enhanced catalysis of ribonuclease B folding by the interaction of calnexin or calreticulin with ERp57. J Biol Chem 1998;273(11):6009–12. doi: 10.1074/jbc.273.11.6009.
- Ning L., Qui-Mei Y., Gale R.P. et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. Leuk Rec 2015;39(5):510–4.
- Jones A.V., Ward D., Lyon M. et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 2015;39(1):82–7. doi: 10.1016/j.leukres.2014.11.019. Available at: https://www.lrjournal.com/ article/S0145-2126(14)00371-3/abstract.
- Luo W., Zhongxin Yu.Z. Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investig 2015;2:16. doi: 10.3978/j.issn.23069759.2015.08.01. Available at: http://sci. amegroups.com/article/view/7264/8051.
- Reed G.H., Kent J.O., Witter C.T. Highresolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 2007;8(6):597–608. doi: 10.2217/14622416.8.6.597
Supplementary files


